Coevolution and HBV drug resistance

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 505-515

  Khudyakov, Yury ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RNA POLYMERASE; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; COEVOLUTION; GENE FREQUENCY; GENE REPLICATION; GENETIC EPISTASIS; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS MUTATION; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; MOLECULAR EVOLUTION; MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MUTATION;

EID: 77953465335     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1515     Document Type: Review

References (100)

1. Harrison TJ. Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 2006; 26:87-96.
2. Khudyakov YE, Makhov AM. Prediction of terminal protein and ribonuclease H domains in the gene P product of hepadnaviruses. FEBS Lett 1989; 243:115-118.
3. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990; 64:613-620.
4. Ohkawa K, Takehara T, Kato M, et al. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 2008; 198:1150-1158.
5. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-1608.
6. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
7. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009; 6:453-462.
8. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14 Suppl 1:29-36.
9. Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80:643-653.
10. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009; 49:50-59.
11. Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181:1221-1233.
12. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261.
13. Zhou Y, Holmes EC. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J Mol Evol 2007; 65:197-205.
14. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9:267-276.
15. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595-597.
16. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 1998; 148:1667-1686.
17. Blum HE. Hepatitis B virus: significance of naturally occurring mutants. Intervirology 1993; 35:40-50.
18. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25-137.
19. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398-4402.
20. Lee JY, Locarnini S. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. Clin Liver Dis 2004; 8:301-320.
21. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34 Suppl 1:S139-S142.
22. Domingo E, Gonzalez-Lopez C, Pariente N, Airaksinen A, Escarmis C. Population dynamics of RNA viruses: the essential contribution of mutant spectra. Arch Virol Suppl 2005; 19:59-71.
23. Azevedo L, Suriano G. van AB, Harding RM, Amorim A. Epistatic interactions: how strong in disease and evolution? Trends Genet 2006; 22:581-585.
24. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ. Evidence for positive epistasis in HIV-1. Science 2004; 306:1547-1550.
25. de Visser JA, Elena SF. The evolution of sex: empirical insights into the roles of epistasis and drift. Nat Rev Genet 2007; 8:139-149.
26. Hartman JL IV, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science 2001; 291:1001-1004.
27. Kouyos RD, Silander OK, Bonhoeffer S. Epistasis between deleterious mutations and the evolution of recombination. Trends Ecol Evol 2007; 22:308-315.
28. Phillips PC. Epistasis - the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008; 9:855-867.
29. Weinreich DM, Watson RA, Chao L. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 2005; 59:1165-1174.
30. Sanjuan R, Moya A, Elena SF. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A 2004; 101:15376-15379. (Pubitemid 39441549)
31. Sanjuan R, Elena SF. Epistasis correlates to genomic complexity. Proc Natl Acad Sci U S A 2006; 103:14402-14405.
32. Wagner A. Robustness, evolvability, and neutrality. FEBS Lett 2005; 579:1772-1778.
33. Wagner A. Robustness and evolvability: a paradox resolved. Proc Biol Sci 2008; 275:91-100.
34. Wagner A. Neutralism and selectionism: a network-based reconciliation. Nat Rev Genet 2008; 9:965-974.
35. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
36. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42:302-308.
37. Gerrish PJ, Lenski RE. The fate of competing beneficial mutations in an asexual population. Genetica 1998; 102-103:127-144.
38. Miralles R, Gerrish PJ, Moya A, Elena SF. Clonal interference and the evolution of RNA viruses. Science 1999; 285:1745-1747.
39. Campos PR, de Oliveira VM. Mutational effects on the clonal interference phenomenon. Evolution 2004; 58:932-937.
40. Campos PR, Wahl LM. The effects of population bottlenecks on clonal interference, and the adaptation effective population size. Evolution 2009; 63:950-958.
41. Kim Y, Orr HA. Adaptation in sexuals vs. asexuals: clonal interference and the Fisher-Muller model. Genetics 2005; 171:1377-1386.
42. Miralles R, Moya A, Elena SF. Diminishing returns of population size in the rate of RNA virus adaptation. J Virol 2000; 74:3566-3571.
43. Pepin KM, Wichman HA. Experimental evolution and genome sequencing reveal variation in levels of clonal interference in large populations of bacteriophage phiX174. BMC Evol Biol 2008; 8:85.
44. Comeron JM, Williford A, Kliman RM. The Hill-Robertson effect: evolutionary consequences of weak selection and linkage in finite populations. Heredity 2008; 100:19-31. (Pubitemid 350293641)
45. Liu Y, Mullins JI, Mittler JE. Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection. Virology 2006; 347:140-146.
46. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
47. + T cell immunity and viral escape following acute HIV-1 infection. J Immunol 2003; 171:3837-3846.
48. Meyerhans A, Dadaglio G, Vartanian JP, et al. In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 1991; 21:2637-2640.
49. Chen L, Zhang Q, Yu DM, Wan MB, Zhang XX. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol 2009; 50:895-905.
50. Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000; 33:469-475. (Pubitemid 30663385)
51. Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009; 119:225-236.
52. Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y. Coordinated evolution of the hepatitis C virus. Proc Natl Acad Sci U S A 2008; 105:9685-9690.
53. Eigen M. Viral quasispecies. Sci Am 1993; 269:42-49.
54. Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987; 41:409-433.
55. Holmes EC, Moya A. Is the quasispecies concept relevant to RNA viruses? J Virol 2002; 76:460-465. (Pubitemid 33139035)
56. Codoner FM, Daros JA, Sole RV, Elena SF. The fittest versus the flattest: experimental confirmation of the quasispecies effect with subviral pathogens. PLoS Pathog 2006; 2:e136.
57. Sanjuan R, Cuevas JM, Furio V, Holmes EC, Moya A. Selection for robustness in mutagenized RNA viruses. PLoS Genet 2007; 3:e93. (Pubitemid 47015854)
58. Wilke CO. Quasispecies theory in the context of population genetics. BMC Evol Biol 2005; 5:44.
59. Sardanyes J, Elena SF, Sole RV. Simple quasispecies models for the survival-of-the-flattest effect: the role of space. J Theor Biol 2008; 250:560-568.
60. Wilke CO, Wang JL, Ofria C, Lenski RE, Adami C. Evolution of digital organisms at high mutation rates leads to survival of the flattest. Nature 2001; 412:331-333. (Pubitemid 32691846)
61. van Nimwegen E, Crutchfield JP, Huynen M. Neutral evolution of mutational robustness. Proc Natl Acad Sci U S A 1999; 96:9716-9720.
62. Wilke CO, Adami C. Evolution of mutational robustness. Mutat Res 2003; 522:3-11.
63. Cuevas JM, Moya A, Sanjuan R. A genetic background with low mutational robustness is associated with increased adaptability to a novel host in an RNA virus. J Evol Biol 2009; 22:2041-2048.
64. Hermisson J, Wagner GP. The population genetic theory of hidden variation and genetic robustness. Genetics 2004; 168:2271-2284. (Pubitemid 40066360)
65. Krakauer DC, Plotkin JB. Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci U S A 2002; 99:1405-1409.
66. West SA, Griffin AS, Gardner A, Diggle SP. Social evolution theory for microorganisms. Nat Rev Microbiol 2006; 4:597-607.
67. West SA, Griffin AS, Gardner A. Social semantics: altruism, cooperation, mutualism, strong reciprocity and group selection. J Evol Biol 2007; 20:415-432. (Pubitemid 46270570)
68. Buckling A, Brockhurst MA. Kin selection and the evolution of virulence. Heredity 2008; 100:484-488.
69. West SA, Griffin AS, Gardner A. Evolutionary explanations for cooperation. Curr Biol 2007; 17:R661-R672.
70. Hamilton WD. The genetical evolution of social behaviour. I. J Theor Biol 1964; 7:1-16.
71. Hamilton WD. The genetical evolution of social behaviour. II. J Theor Biol 1964; 7:17-52.
72. Garcia-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmis C. Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 2004; 78:11678-11685. (Pubitemid 39390754)
73. Finzi D, Plaeger SF, Dieffenbach CW. Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol 2006; 13:715-721.
74. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A 1996; 93:2239-2244.
75. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006; 439:344-348. (Pubitemid 43128860)
76. Shriner D, Liu Y, Nickle DC, Mullins JI. Evolution of intrahost HIV-1 genetic diversity during chronic infection. Evolution 2006; 60:1165-1176. (Pubitemid 44804475)
77. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88-98. (Pubitemid 351975534)
78. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
79. Marschenz S, Brinckmann A, Nurnberg P, Kruger DH, Gunther S, Meisel H. Co-replication analyses of naturally occurring defective hepatitis B virus variants with wild-type. Virology 2008; 372:247-259. (Pubitemid 351273750)
80. Preikschat P, Gunther S, Reinhold S, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35:466-477. (Pubitemid 34106390)
81. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 Suppl 5:S45-S55.
82. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13:1770-1787. (Pubitemid 46706009)
83. Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis B e antigen seroconversion. Gastroenterology 2007; 133:951-958. (Pubitemid 47381357)
84. Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 2000; 81:75-83. (Pubitemid 30047908)
85. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-852. (Pubitemid 47374140)
86. Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40:727-737. (Pubitemid 39265596)
87. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-855.
88. Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat 2009; 16:223-229.
89. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005; 102:1139-1144. (Pubitemid 40170739)
90. Mason WS, Low HC, Xu C, et al. Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J Virol 2009; 83:8396-8408.
91. Mason WS, Litwin S, Xu C, Jilbert AR. Hepatocyte turnover in transient and chronic hepadnavirus infections. J Viral Hepat 2007; 14 Suppl 1:22-28. (Pubitemid 47624108)
92. Mason WS, Litwin S, Jilbert AR. Immune selection during chronic hepadnavirus infection. Hepatol Int 2008; 2:3-16. (Pubitemid 351250399)
93. Thompson A, Locarnini S, Visvanathan K. The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology 2007; 133:1031-1035. (Pubitemid 47374157)
94. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6:573-580.
95. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:1041-1050.
96. Walters KA, Joyce MA, Addison WR, Fischer KP, Tyrrell DL. Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen. J Virol 2004; 78:7925-7937.
97. Tscherne DM, Evans MJ, von Hahn T, et al. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 2007; 81:3693-3703. (Pubitemid 46586866)
98. Whitaker-Dowling P, Youngner JS, Widnell CC, Wilcox DK. Superinfection exclusion by vesicular stomatitis virus. Virology 1983; 131:137-143. (Pubitemid 14248605)
99. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:1615-1621. (Pubitemid 28304597)
100. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74:5257-5265. (Pubitemid 30313867)